CLUN20055 / EA5181 / Arpan Patel, MDResearch Question:
How well does durvalumab, an antibody, work when added to chemoradiation for treating
patients with lung cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and
radiation therapy (chemoradiation) works in treating patients with stage III non-small
cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with
monoclonal antibodies, such as durvalumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread.
This study is being done to see if adding durvalumab to standard chemoradiation followed
by additional durvalumab can extend patients life and/or prevent the tumor from coming
back compared to the usual approach of chemoradiation alone followed by durvalumab.
Study Reference #: CLUN20055
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Nichole Ransom
Phone: +1 585-276-8747
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search